Assessing cilnidipine and its combination usage in Indian settings: a knowledge, attitude, and practice survey

Mukesh Shete; Ashish Saxena; Akshay Nakrani; Chirag  Shah; Heena Bhojwani; Dinesh Jiwane

doi:10.18203/2349-3933.ijam20243058

Authors

Mukesh Shete Jupiter Lifeline Hospital, Thane, Maharashtra, India
Ashish Saxena Diabetes and Heart Centre and SPS Hospital, Ludhiana, Punjab, India
Akshay Nakrani Aastha Life Care Hospital, Mumbai, Maharashtra, India
Chirag Shah Apex Hospital, Mumbai, Maharashtra, India
Heena Bhojwani Medical Services, Alembic Pharmaceuticals Ltd, Mumbai, Maharashtra, India
Dinesh Jiwane Medical Services, Alembic Pharmaceuticals Ltd, Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/2349-3933.ijam20243058

Keywords:

Hypertension, Cilnidipine, Telmisartan, KAP survey, India

Abstract

Background: Hypertension, affecting 31% of the Indian population, is a major risk factor for cardiovascular diseases. Cilnidipine is used in its management, alone or in combination with ARB. The objective of the current KAP survey was to assess the knowledge of healthcare professionals (HCPs) regarding hypertension management, their attitudes toward its treatment, and the application of this knowledge in clinical practice.

Method: A pan-India cross-sectional KAP survey was conducted from April 2022 to March 2023. The survey utilized a specially designed questionnaire focusing on various aspects of using cilnidipine and its combination with Telmisartan in hypertension management. A total of 1,254 HCPs with recognized qualifications participated. Descriptive statistics were employed for data analysis.

Results: Around 56% of HCPs initiated monotherapy of an antihypertensive drug at an SBP level of 140 mmHg, while 57% initiated combination therapy at an SBP>160 mmHg. Nearly 43% reported initiating combination therapy in 20-30% of patients as initial treatment. Cilnidipine was preferred over amlodipine mainly due to decreased pedal edema. Cilnidipine monotherapy benefits young hypertensive patients (46%) and those with chronic kidney disease (CKD, 44%). Cilnidipine and telmisartan combination benefits patients with uncontrolled hypertension (46%), diabetes (43%), and CKD (41%). Advantages of this combination include less fluid retention, better compliance and tolerability, and less pedal edema.

Conclusion: This KAP survey highlights current practices in hypertension management, emphasizing the use of cilnidipine and its combination, attributed to their favorable tolerability and suitability for diverse patient profiles.

Metrics

Metrics Loading ...

References

Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. 2022;328(18):1849-61.

Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2018;71(19):127-248.

Global report on hypertension. Available at. https://www.who.int/publications/i/item/9789240081062. Accessed on 29th April, 2024.

Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474-89.

Chandra KS, Ramesh G. The fourth-generation Calcium channel blocker: cilnidipine. Indian Heart J. 2013;65(6):691-5.

Chakraborty RN, Langade D, More S, Revandkar V, Birla A. Efficacy of cilnidipine (L/N-type calcium channel blocker) in treatment of hypertension: a meta-analysis of randomized and non-randomized controlled trials. Cureus. 2021;13(11):19822.

Nagahama S, Norimatsu T, Maki T, Yasuda M, Tanaka S. The effect of combination therapy with an L/N-Type Ca (2+) channel blocker, cilnidipine, and an angiotensin II receptor blocker on the blood pressure and heart rate in Japanese hypertensive patients: an observational study conducted in Japan. Hypertens Res. 2007;30(9):815-22.

Shah AP, Parmar SA, Kumkishan A, Mehta A. Knowledge, Attitude and Practice (KAP) Survey Regarding the safe use of Medicines in rural area of Gujurat. Adv Trop Med Pub Health. 2011;1(2):66-70.

Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA). J Hypertens. 2023;41(12):1874-2071.

Adake P, Somashekar HS, Mohammed Rafeeq PK, Umar D, Basheer B, Baroudi K. Comparison of amlodipine with cilnidipine on antihypertensive efficacy and incidence of pedal edema in mild to moderate hypertensive individuals: A prospective study. J Adv Pharm Technol Res. 2015;6(2):81-5.

Harlalka S, Roy UK, Majumdar G, Das K, Mandal P. An open label prospective study on evaluation of safety and efficacy of cilnidipine over amlodipine in stage 1 hypertensive patients. Kathmandu Univ Med J (KUMJ). 2020;18(69):42-8.

Jj NK, D DC, Kavitha R. A randomized open-label parallel-group study comparing the efficacy and safety of cilnidipine and amlodipine in hypertensive adults. J Assoc Physicians India. 2022;69(12):11-2.

Hamada T, Yamada K, Mizuta E, Watanabe A, Osaki T, Ishida K, et al. Effects of cilnidipine on serum uric acid level and urinary nitrogen monoxide excretion in patients with hypertension. Clin Exp Hypertens. 2012;34(7):470-3.

Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res. 2004;27(6):379-85.

Abe M, Maruyama N, Suzuki H, Inoshita A, Yoshida Y, Okada K, et al. L/N-type calcium channel blocker cilnidipine reduces plasma aldosterone, albuminuria, and urinary liver-type fatty acid binding protein in patients with chronic kidney disease. Heart Vessels. 2013;28(4):480-9.

Soeki T, Kitani M, Kusunose K, Yagi S, Taketani Y, Koshiba K, et al. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertens Res. 2012;35(11):1058-62.

Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther. 2009r;27(2):124-39.

Dharpur PM, Kavitha VC. A study at BRIMS hospital for comparing the tolerability of Cilnidipine and Amlodipine in the treatment of hypertension. Indian J Pharm Pharmacol. 2019;6(1):11-3.

Kumar M, Bhuvaneshvari S, Shanmugham T, Kumar G, Kumar A. Comparing the effectiveness and safety of amlodipine vs. cilnidipine for mild to moderate hypertension. JCDR. 2024;12(5):1527-36.

Jo JH, Lee DH, Han JH, Lee M, Jang KW, Myung CS. Effects of combination treatment with cilnidipine and telmisartan on hypertension, cardiovascular injury, and high blood glucose. J Pharma Invest. 2021;51:337-46.

Ram CVS, Muppalla BS, Parthasaradhi SV, Kumar GP, Ray S, Jadhav U, et al. Achieving the latest American heart association and American college of cardiology therapeutic goals for hypertension With combination therapy and its effects on blood pressure and central hemodynamic parameters. Am J Cardiol. 2022;168:78-82.

Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, et al. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int. 2007;72(12):1543-9.

Prasad RS. Replacement of Amlodipine with Cilnidipine and assessment of pedal edema along with blood pressure control. J Appl Med Sci. 2015;3(4A):1680-2.

Kafle RC, Sapkota S, Maskey A. Cilnidipine for amlodipine induced pedal edema and its anti-hypertensive effect in a tertiary care teaching hospital of western Nepal. Med Pub Health. 2013;44(2):1-5.